Johnson & Johnson (J&J) reported strong second-quarter earnings, exceeding Wall Street estimates on robust drug sales. Key drivers included the cancer treatment Darzalex and the blockbuster psoriasis drug Stelara, which saw sales increase by 18.4% …
Continue reading